Ernexa Therapeutics Inc 8-K, filed Sep 23, 2022
Ernexa Therapeutics Inc. (ERNA)
8-K
2022-09-23
For: 2022-09-21
View Original
Added on
April 06, 2026
About this 8-K
Ernexa Therapeutics Inc filed this 8-K on September 23, 2022, reporting on events of September 21, 2022.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 21, 2022
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
||
|
|
||
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (212 ) 582-1199
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange
Act of 1934:
|
Emerging growth company
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
On September 21, 2022, Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), held its 2022 Annual Meeting of Stockholders
(the “Annual Meeting”). The final voting results for the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are as follows:
Proposal 1: Election of five directors to the Board of Directors of the Company
to hold office until the Company’s 2023 Annual Meeting of Stockholders or until their respective successors are elected and qualified:
|
Director
|
Votes
For
|
Votes
Withheld
|
Broker
Non-Votes
|
|||
|
Charles Cherington
|
24,960,908
|
3,213,277
|
14,849,874
|
|||
|
Matthew Angel
|
26,060,381
|
2,113,804
|
14,849,874
|
|||
|
Nicholas J. Singer
|
26,037,962
|
2,136,223
|
14,849,874
|
|||
|
Gregory Fiore
|
25,923,220
|
2,250,965
|
14,849,874
|
|||
|
William Wexler
|
26,044,952
|
2,129,233
|
14,849,874
|
Proposal 2: Approval of a non-binding advisory resolution approving the
compensation of the Company’s named executive officers as disclosed in the Company’s 2022 Proxy Statement for the Annual Meeting:
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
|||
|
23,660,694
|
4,462,421
|
51,070
|
14,849,874
|
Proposal 3: Ratification of the appointment of Grant Thornton LLP as the
Company’s independent registered public accounting firm for the 2022 fiscal year:
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
|||
|
42,584,506
|
373,779
|
65,774
|
—
|
Proposal 4: Approval of the amendment to the Company’s Restated Certificate of
Incorporation, as amended, to effect a reverse stock split (the “Reverse Stock Split”) with respect to the Company’s issued and outstanding common stock, par value $0.005 per share, at a ratio of 1-for-10 to 1-for-20 (the “Range”),
with the ratio at which the Reverse Stock Split would be effected to be a ratio within the Range to be determined at the discretion of the Company’s Board of Directors:
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
|||
|
40,383,795
|
2,603,310
|
36,954
|
—
|
No other matters were considered or voted upon at the Annual Meeting.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
Brooklyn ImmunoTherapeutics, Inc.
|
||
|
Dated: September 23, 2022
|
By:
|
/s/ Andrew Jackson
|
|
Chief Financial Officer
|
||